DNTOX
Germany
- Düsseldorf
- 19/06/2023
- Seed
- $1,529,738
We are building up a bioanalytical testing laboratory for animal-free screening of chemicals, regarding their potential to disturb brain development and cause developmental neurotoxicity (DNT).
Our in vitro testing battery is based on human cell models and enables chemical screening in a high-content and medium-throughput fashion. Furthermore, it is supported by an in-house developed software, using artifical intelligence.
We support our customers during the identification of safe lead structures during substance development, as well as the safety assessment during approval and re-approval processes of chemicals.
With our innovation, we want to realize our company vision:
Safe chemicals without animal experiments!
- Industry Research
- Website https://dntox.de/
- LinkedIn https://www.linkedin.com/company/dntox/
Iceotope | $26,000,000 | (May 15, 2026)
Harken Sweets | Undisclosed Amount | (May 15, 2026)
Graphon AI | $8,300,000 | (May 15, 2026)
Ranger AI | $8,400,000 | (May 15, 2026)
Wirestock | $23,000,000 | (May 15, 2026)
GridCARE | $64,000,000 | (May 15, 2026)
Chromie Health | $2,000,000 | (May 15, 2026)
Novella | $21,000,000 | (May 15, 2026)
Flick | $6,000,000 | (May 15, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)